Integra LifeSciences voluntarily recalls all CereLink ICP monitors; cuts guidance by $9M

INTEGRA LIFESCIENCES HOLDINGS CORP

Voluntary global removal of all CereLink intracranial pressure monitors due to out-of-range readings from electrical interference.
Records $9M returns provision in Q3 2022; Q3 revenue guidance lowered to $374-382M from $383-391M.
Full-year revenue guidance reduced to $1,548-1,566M from $1,557-1,575M; adjusted EPS lowered to $3.12-3.20 from $3.21-3.29.
Low incidence rate at limited sites; investigation ongoing; plans to resume shipments after resolution.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.